The Lancet Oncology Publishes Results Of XGEVA® (denosumab) In Patients With Giant Cell Tumor Of Bone

 The Lancet Oncology Publishes Results Of XGEVA® (denosumab) In Patients With
                           Giant Cell Tumor Of Bone

Phase 2 Study Reports Safety and Efficacy Results

PR Newswire

THOUSAND OAKS, Calif., July 15, 2013

THOUSAND OAKS, Calif., July 15, 2013 /PRNewswire/ --Amgen (NASDAQ:AMGN) today
announced the Lancet Oncology published planned interim results from an
international, open-label, Phase 2 clinical trial that is evaluating XGEVA^®
(denosumab) in adults and skeletally mature adolescents diagnosed with giant
cell tumor of bone (GCTB). The study's primary endpoint is the safety profile
of XGEVA. Secondary endpoints are the time to disease progression and the
proportion of patients without any surgery at six months.

Based on the investigators' interim assessment, 96 percent (163/169) of
patients with surgically unsalvageable GCTB had no disease progression after a
median follow-up of 13 months. In those with salvageable GCTB whose surgery
was associated with severe morbidity, 74 percent (74/100) of patients required
no surgery, and 62 percent (16/26) of patients who had surgery underwent a
less morbid procedure than planned. Overall, 72 percent of patients had
objective tumor response, per protocol defined criteria, including 25 percent
of patients who had an objective tumor response according to modified
RECIST(Response Evaluation Criteria In Solid Tumors).

The overall safety profile was found to be consistent with the known safety
profile of XGEVA in patients with advanced cancer. Osteonecrosis of the jaw
was reported in one percent (3/281) of patients. Hypocalcemia adverse events,
all non-serious, were reported in five percent (15/281) of patients. The most
common severe adverse events were low phosphate levels, back pain, pain in
extremity, depression, musculoskeletal pain and anemia. Serious adverse events
were reported in nine percent (25/281) of patients. No treatment-related
deaths were reported.

"These results demonstrate the effectiveness of XGEVA in the treatment of
giant cell tumor of bone and reinforce our understanding of this rare disease
in which RANK Ligand plays a central role," said Sean E. Harper, M.D.,
executive vice president of Research and Development at Amgen. "XGEVA
represents a much needed treatment option for patients who suffer from giant
cell tumor of bone that can't be adequately treated with surgery."

GCTB is a rare, osteolytic tumor of the bone that often results in complete
destruction of the affected bone, leading to bone fracture, joint dysfunction,
deformity or amputation. GCTB typically affects individuals between the ages
of 20 to 40.

XGEVA was approved June 13, 2013 by the U.S. Food and Drug Administration
(FDA) for the treatment of adults and skeletally mature adolescents with GCTB
that is unresectable or where surgical resection is likely to result in severe
morbidity. The approval followed a priority review by the FDA, a designation
reserved for drugs that offer major advances in treatment, or provide a
treatment where no adequate therapy exists. Prior to approval, there had been
no approved therapies for GCTB. Surgery is the main treatment option for
patients with resectable GCTB. This study is one of two clinical trials on
which the FDA approval was based.

XGEVA is a fully human monoclonal antibody that binds to RANK Ligand (RANKL),
a protein essential for the formation, function and survival of osteoclasts -
the cells responsible for bone resorption. Giant cell tumors of bone consist
of stromal cells expressing RANKL and osteoclast-like giant cells expressing
RANK receptor. Signaling through the RANK receptor contributes to osteolysis
and tumor growth. XGEVA prevents RANKL from activating its receptor, RANK, on
the surface of osteoclasts, their precursors and osteoclast-like giant cells.

Study Design
In this international, open-label, Phase 2 study, 282 patients with confirmed
GCTB and measurable, active disease were divided into three cohorts: patients
with surgically unsalvageable GCTB (Cohort 1), patients with salvageable GCTB
whose surgery was associated with severe morbidity (Cohort 2), or patients who
transferred from a previous XGEVA GCTB study (Cohort 3). All three cohorts
received subcutaneous XGEVA 120 mg every four weeks with loading doses on days
eight and 15. The primary endpoint is the safety profile of XGEVA in terms of
adverse events and laboratory abnormalities. Secondary endpoints of the study
vary by cohort and include time to disease progression and the proportion of
patients without any surgery at six months.

About Giant Cell Tumor of Bone
GCTB is a locally aggressive, benign tumor primarily afflicting younger adults
between the ages 20 to 40.^1,2 It is estimated that there are approximately
300 to 800 new cases of GCTB annually in the U.S. GCTB is unresectable in
approximately 18 to 20 percent of cases.^3

Most GCTB tumors occur in the long bones of the body, often around joints, but
can also spread to the lungs in rare cases.^4,5 Although giant cell tumors are
slow growing, patients can experience severe bone pain, soft tissue and joint
swelling, loss of mobility and pathologic fracture.^4,5 Historically, there
have been no approved therapies for GCTB. Surgery is the main treatment option
for patients with resectable GCTB; however, surgery, such as amputation, may
be associated with significant morbidity.^1 These tumors also have a higher
recurrence rate within the first three years of surgical intervention.^1 When
tumors recur, they become more difficult to treat and more likely to spread to
other parts of the body.^1

About XGEVA
XGEVA was approved by the FDA for the prevention of skeletal-related events
(SREs) in patients with bone metastases from solid tumors in 2010. XGEVA is
not indicated for the prevention of SREs in patients with multiple myeloma. In
clinical trials, XGEVA demonstrated a clinically meaningful improvement
compared to the previous standard of care in preventing these bone
complications.

In 2013, XGEVA was approved by the FDA as the first-and-only treatment for
adults and skeletally mature adolescents with GCTB that is unresectable or
where surgical resection is likely to result in severe morbidity.

XGEVA Important Safety Information

Hypersensitivity
XGEVA is contraindicated in patients with clinically significant
hypersensitivity to any component of the product.

Hypocalcemia
XGEVA can cause severe symptomatic hypocalcemia, and fatal cases have been
reported. Correct pre-existing hypocalcemia prior to XGEVA treatment. Monitor
calcium levels and administer calcium, magnesium, and vitamin D as necessary.
Advise patients to contact a healthcare professional for symptoms of
hypocalcemia.

Osteonecrosis of the Jaw (ONJ)
Osteonecrosis of the jaw (ONJ) can occur in patients receiving XGEVA. Patients
who are suspected of having or who develop ONJ while on XGEVA should receive
care by a dentist or an oral surgeon. In these patients, extensive dental
surgery to treat ONJ may exacerbate the condition.

Atypical Subtrochanteric and Diaphyseal Femoral Fracture
Atypical femoral fracture has been reported with XGEVA. Causality has not been
established as these fractures also occur in osteoporotic patients who have
not been treated with anti-resorptive agents. A number of reports note that
patients were also receiving treatment with glucocorticoids at the time of
fracture. Any patient who presents with thigh or groin pain should be
suspected of having an atypical fracture and should be evaluated to rule out
an incomplete femur fracture. Interruption of XGEVA therapy should be
considered, pending a risk/benefit assessment, on an individual basis.

Embryo-Fetal Toxicity
XGEVA can cause fetal harm when administered to a pregnant woman. Advise
females of reproductive potential to use highly effective contraception during
therapy, and for at least 5 months after with the last dose of XGEVA.

Adverse Reactions
The most common adverse reactions in patients receiving XGEVA with bone
metastasis from solid tumors were fatigue/asthenia, hypophosphatemia, and
nausea. The most common serious adverse reaction was dyspnea.

The most common adverse reactions in patients receiving XGEVA for giant cell
tumor of bone were arthralgia, headache, nausea, back pain, fatigue, and pain
in extremity. The most common serious adverse reactions were osteonecrosis of
the jaw and osteomyelitis.

Please visitwww.amgen.comfor full prescribing information.

About Amgen
Amgendiscovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980,Amgenwas one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient.Amgen therapeutics have
changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new
medicines,Amgenremains committed to advancing science to dramatically
improve people's lives. For more information, visit www.amgen.comand follow
us onwww.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in theSecurities and Exchange Commission(SEC) reports filed
byAmgen, includingAmgen'smost recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer
toAmgen'smost recent Forms 10-K, 10-Q and 8-K for additional information on
the uncertainties and risk factors related to our business. Unless otherwise
noted,Amgenis providing this information as ofJuly 15, 2013, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government investigations,
litigation and product liability claims. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the U.S.
government, we could become subject to significant sanctions. We depend on
third parties for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product candidate
development.

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant
problems with a product similar to one of our products that implicate an
entire class of products could have a material adverse effect on sales of the
affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new
indications for our products is preliminary and investigative and is not part
of the labeling approved by theU.S. Food and Drug Administration(FDA) for
the products. The products are not approved for the investigational use(s)
discussed in this news release, and no conclusions can or should be drawn
regarding the safety or effectiveness of the products for these uses. Only
theFDAcan determine whether the products are safe and effective for these
uses. Healthcareprofessionals shouldrefer to and rely upon theFDA-approved
labeling for the products, and not the information discussed in this news
release.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

^1 Thomas D, Henshaw R, Skubitz K, et. al. Denosumab in patients with
giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol.
2010;11:275–280.
^2 MeSH Descriptor Data. National Library of Medicine - Medical Subject
Headings website.
http://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?mode=&term=Giant+Cells. Accessed
June 24, 2013.
^3 Thomas DM, Skubitz KM. Giant cell tumour of bone. Current Opinion in
Oncology. 2009;21:338-344.
^4 Bone Cancer. American Cancer Society website.
http://www.cancer.org/Cancer/BoneCancer/DetailedGuide/bone-cancer-what-is-bone-cancer.
Accessed June 24, 2013.
^5 Giant Cell Tumor of Bone. American Academy of Orthopaedic Surgeons website.
http://orthoinfo.aaos.org/topic.cfm?topic=a00080. Accessed June 24, 2013.

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.